journal
https://read.qxmd.com/read/38236726/predicting-glucocorticoid-effectiveness-in-thyroid-eye-disease-combined-value-from-serological-lipid-metabolism-and-orbital-mri-parameter
#21
JOURNAL ARTICLE
Haitao Zhang, Hao Hu, Yueyue Wang, Xinjie Duan, Lu Chen, Jiang Zhou, Wen Chen, Weizhong Zhang, Xiaoquan Xu, Huanhuan Chen
PURPOSE: To determine the combined value of serological lipid metabolism and an orbital magnetic resonance imaging (MRI) quantitative parameter in predicting the effectiveness of glucocorticoid (GC) therapy in patients with thyroid eye disease (TED). METHODS: This study retrospectively enrolled 46 patients with active and moderate-to-severe TED (GC-effective group, n = 29; GC-ineffective group, n = 17). Serological lipid metabolism, the orbital MRI-based minimum signal intensity ratio of extraocular muscles (EOM-SIRmin) as well as other clinical parameters before GC therapy were collected and compared between the two groups...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38215286/selenium-supplementation-and-placebo-are-equally-effective-in-improving-quality-of-life-in-patients-with-hypothyroidism
#22
JOURNAL ARTICLE
Camilla Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmusssen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedus, Steen Joop Bonnema
PURPOSE: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479). METHODS: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38215285/psychiatric-complications-in-graves-disease
#23
JOURNAL ARTICLE
Mats Holmberg, Helge Malmgren, Peter Berglund, Birgitta Johansson, Helena Filipsson Nyström
BACKGROUND: Mood disorders are common in Graves' disease despite treatment. The pathogenic mechanisms involved are unknown and so is whether previous psychiatric disease influences these symptoms. METHODS: This is a longitudinal study conducted in Sweden, on 65 women with newly diagnosed Graves' disease and 65 matched controls. Participants were examined during hyperthyroidism and after 15 months of treatment. Examinations included blood sampling, and psychiatric testing with the Comprehensive Psychopathological Rating Scale for Affective Syndromes and the Structured Clinical Interview for DSM-IV-Axis I Disorders...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38198295/the-diagnostic-utility-of-repeat-fine-needle-aspirations-of-benign-thyroid-nodules
#24
JOURNAL ARTICLE
Rachelle Mendoza, Richard Cody Simon, Nicole A Cipriani, Tatjana Antic
Objective This study aims to analyze the diagnostic utility of multiple repeat FNA on thyroid nodules with initially benign diagnosis. Methods In a 5-year period, 1658 thyroid nodules with initially benign FNAs were retrospectively reviewed and followed for subsequent resection and repeat biopsy. Results Out of 2150 thyroid nodules, 1658 (77.1%) were diagnosed as benign on FNAs. The average age was 57.4 years (range 11-93 years), and most were females (83.8%). Repeat FNA was performed on 183 benign nodules, of which 141 (8...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38189657/real-world-clinical-profile-ret-mutation-testing-treatments-and-pros-for-mtc-in-europe
#25
JOURNAL ARTICLE
Grace Segall, Ravinder Singh, Min-Hua Jen, Isaac Sanderson, Alex Rider, Katie Lewis, Urpo Kiiskinen
OBJECTIVE: This study aimed to describe real-world patient and physician characteristics, rearranged during transfection (RET) mutation testing and results, treatment patterns, and patient-reported outcomes (PROs) in advanced or metastatic medullary thyroid cancer (aMTC) across five populous European countries. METHODS: Cross-sectional physician and patient surveys were used to collect quantitative and qualitative data in France, Germany, Italy, Spain, and the UK from July to December 2020, prior to the introduction of selective RET inhibitors in Europe...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38189656/association-of-sensitivity-to-thyroid-hormones-with-all-cause-mortality-in-euthyroid-us-adults-a-nationwide-cohort-study
#26
JOURNAL ARTICLE
Genfeng Yu, Siyang Liu, Cheng Song, Qintao Ma, Xingying Chen, Yuqi Jiang, Hualin Duan, Yajun He, Dongmei Wang, Heng Wan, Jie Shen
Background This study aimed to examine the associations of thyroid hormone sensitivity indices, including free triiodothyronine to free thyroxine (FT3/FT4) ratio, thyroid feedback quantile-based index by FT4 (TFQIFT4), thyroid-stimulating hormone index (TSHI), and thyrotrophic thyroxine resistance index (TT4RI) with all-cause mortality in euthyroid adults. Methods The study included 6243 euthyroid adults from the National Health and Nutrition Examination Survey (NHANES) 2007-2012. FT3/FT4 ratio, TFQIFT4, TSHI, and TT4RI were calculated...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38181007/combinatorial-hypofractionated-radiotherapy-and-pembrolizumab-in-anaplastic-thyroid-cancer
#27
JOURNAL ARTICLE
Janice Ser Huey Tan, Timothy Kwang Yong Tay, Enya Hui Wen Ong, Michael Fehlings, Daniel Shao-Weng Tan, Nadiah Binte Sukma, Eileen Xueqin Chen, Jen-Hwei Sng, Connie Siew Poh Yip, Kok Hing Lim, Darren Wan-Teck Lim, Narayanan Gopalakrishna Iyer, Jacqueline Siok Gek Hwang, Melvin Lee Kiang Chua, Mei-Kim Ang
Objectives Anaplastic thyroid cancer (ATC) is an aggressive disease associated with poor outcomes and resistance to therapies. Our study aim was to evaluate the activity of a combinatorial regimen of sandwich sequencing of pembrolizumab immunotherapy and hypofractionated radiotherapy (RT). Methods In this case series, patients with ATC received hypofractionated RT (QUAD-shot) and intravenous pembrolizumab 200mg every 3-4 weeks. Pembrolizumab was continued until disease progression or up till 24 months. Concurrent Lenvatinib treatment was allowed...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38181005/the-diagnostic-value-of-gica-used-for-intraoperative-lymph-node-fna-tg-measurement-to-evaluate-thyroid-cancer-metastases
#28
JOURNAL ARTICLE
Shaodong Hou, Yiceng Sun, Zeyu Yang, Mi Tang, Tingjie Yin, Cong Shao, Cunye Yan, Linlong Mo, Yuquan Yuan, Supeng Yin, Fan Zhang
OBJECTIVE: It is crucial to diagnose lymph node (LN) metastases (LNM) before or during thyroid carcinoma surgery. Measurement of thyroglobulin (Tg) in fine-needle aspirate washout (FNA-Tg) is useful to assist in the diagnosis of LNM for papillary thyroid carcinoma (PTC). This study aimed to assess the diagnostic performance of a new technique based on a colloidal gold-based immunochromatographic assay (GICA) for intraoperative FNA-Tg in diagnosing LNM. METHODS: This prospective study enrolled 51 PTC patients who underwent cervical LN dissection...
January 1, 2024: European Thyroid Journal
https://read.qxmd.com/read/38096102/real-world-practice-patterns-and-outcomes-for-rai-refractory-differentiated-thyroid-cancer
#29
JOURNAL ARTICLE
Andrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, Marcia S Brose, Lori Wirth, Taofeek Owonikoko, Svetlana Babajanyan, Francis P Worden
BACKGROUND: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes in asymptomatic patients with progressive RAI-R DTC (≥1 lesion ≥1 cm in diameter) in the United States (US) and outside the US (non-US). METHODS: In this prospective, non-interventional, open-label study, eligible patients were chosen by treating physicians to receive MKI therapy (Cohort 1) or undergo active surveillance (Cohort 2) at study entry...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/38052158/activation-of-mitogen-activated-protein-kinase-signaling-and-development-of-papillary-thyroid-carcinoma-in-thyroid-stimulating-hormone-receptor-d633h-knockin-mice
#30
JOURNAL ARTICLE
Markus Eszlinger, Alexandra Stephenson, Shideh Mirhadi, Konrad Patyra, Michael F Moran, Moosa Khalil, Jukka Kero, Ralf Paschke
OBJECTIVE: Nonautoimmune hyperthyroidism (NAH) is rare and occurs due to a constitutively activating thyroid stimulating hormone receptor (TSHR) mutation. In contrast to other thyroid nodules, no further evaluation for malignancy is recommended for hot thyroid nodules. In the first model for NAH in mice nearly all homozygous mice had developed papillary thyroid cancer by 12 months of age. METHODS: To further evaluate these mice, whole exome sequencing and phosphoproteome analysis were employed in a further generation of mice to identify any other mutations potentially responsible and to identify the pathways involved in thyroid carcinoma development...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37992297/clinical-factors-for-choosing-active-surveillance-an-analysis-of-papillary-thyroid-microcarcinoma-patients-with-recurrence
#31
JOURNAL ARTICLE
Ho-Ryun Won, Min Gyu Kim, Min Soo Kim, Jae Won Chang, Bon Seok Koo
OBJECTIVE: Active surveillance (AS) has been suggested as a management option for low-risk papillary thyroid microcarcinoma (PTMC). However, the currently proposed selection criteria for AS application do not consider various clinical factors. The purpose of this study was to analyze clinical factors related to recurrence that could be confirmed preoperatively in patients who underwent surgery for PTMC and to identify factors worth considering when deciding whether to apply AS. MATERIALS AND METHODS: Data were collected from patients with PTMC who underwent surgical treatment at Chungnam National University Hospital...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37992294/autonomously-functioning-thyroid-nodules-present-intermediate-malignancy-risk-according-to-european-thyroid-imaging-reporting-and-data-system-eu-tirads-and-yield-indeterminate-cytology-results
#32
JOURNAL ARTICLE
Aglaia Kyrilli, Nunzia Tacelli, Lucia Russo, Laetitia Lebrun, Isabelle Salmon, Gilles Russ, Rodrigo Moreno-Reyes, Bernard Corvilain
OBJECTIVES: The aim was to evaluate the clinical, ultrasound (US) and, when indicated, the cytological and histological characteristics of autonomously functioning thyroid nodules (AFTN) in consecutive patients. METHODS: A prospective, single-centre study was conducted between March 2018 and September 2021. In total, 901 consecutive patients were referred for thyroid workup and of 67 AFTN were evaluated. All enrolled patients underwent 99mTcO4 - scintigraphy, additional 123I scintigraphy only in case of normal serum TSH, evaluation of thyroid function, US examination using European Thyroid Imaging and Reporting Data System (EU-TIRADS), and US-guided fine needle aspiration (FNA) cytology when indicated...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37992286/effects-of-iodine-status-on-thyroid-volume-and-goiter-in-children-living-in-an-iodine-replete-area
#33
JOURNAL ARTICLE
Yun Jeong Lee, Young Hun Choi, Youn-Hee Lim, Bung-Nyun Kim, Johanna Inhyang Kim, Yun-Chul Hong, Young Joo Park, Choong Ho Shin, Sun Wook Cho, Young Ah Lee
OBJECTIVE: Adequate iodine intake is essential for growing children, and thyroid volume (Tvol) is considered as an indicator of iodine status. We investigated Tvol and goiter using ultrasonography (US) and their association with iodine status in 228 6-year-old children living in Korea. METHODS: Iodine status was assessed using urine iodine concentration (UIC) and categorized as deficient (<100 μg/L), adequate (100-299 μg/L), mild excess (300-499 μg/L), moderate excess (500-999 μg/L), and severe excess (≥1000 μg/L)...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37937795/european-thyroid-journal-passing-on-the-baton
#34
EDITORIAL
S H S Pearce, L Persani
No abstract text is available yet for this article.
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37930957/significance-of-thyroperoxidase-and-thyroglobulin-antibodies-in-medically-treated-graves-disease
#35
JOURNAL ARTICLE
Stefan Matei Constantinescu, Julien Hospel, Chantal Daumerie, Orsalia Alexopoulou, Dominique Maiter, Maria-Cristina Burlacu
BACKGROUND: Thyroperoxidase (TPOAb) and thyroglobulin (TgAb) antibodies are highly prevalent in Graves' disease (GD), but their significance is controversial. METHODS: We retrospectively analyzed TPOAb and TgAb levels and evolution in 136 patients with newly diagnosed GD between 2000 and 2022, treated with anti-thyroid drugs (ATD) in a block-and-replace (B+R) regimen for at least 12 months and followed up for at least 1 year after ATD discontinuation or until disease relapse...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37878416/a-20-year-study-of-autoimmune-polyendocrine-syndrome-type-ii-and-iii-in-taiwan
#36
JOURNAL ARTICLE
Hsu-Hua Tseng, Yen-Bo Lin, Kuan-Yu Lin, Chia-Hung Lin, Hung-Yuan Li, Chia-Hsuin Chang, Yi-Ching Tung, Pei-Lung Chen, Chih-Yuan Wang, Wei-Shiung Yang, Shyang-Rong Shih
PURPOSE: Autoimmune polyendocrine syndrome (APS) is a rare immune-endocrinopathy characterized by the failure of at least two endocrine organs. Clinical characteristics have mainly been described in the Western population. This study comprehensively analyzed the demographic and clinical manifestations of APS II and APS III in Taiwan. METHODS: Patients aged ≥20 years with a diagnosis of APS II or APS III in ten hospitals between 2001 and 2021 were enrolled...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37855426/unnecessary-thyroid-surgery-rate-for-suspicious-nodule-in-the-absence-of-molecular-testing
#37
JOURNAL ARTICLE
Maria Mavromati, Essia Saiji, Marco Stefano Demarchi, Vincent Lenoir, Amanda Seipel, Paulina Kuczma, François R Jornayvaz, Minerva Becker, Eugenio Fernandez, Claudio De Vito, Frédéric Triponez, Sophie Leboulleux
BACKGROUND: Molecular tests for suspicious thyroid nodules decrease rates of unnecessary surgeries but are not widely used due to reimbursement issues. The aim of this study was to assess the rate of unnecessary surgery performed in real-life setting for Bethesda III, IV and V nodules in the absence of molecular testing. METHOD: This is a single-center retrospective study of consecutive patients undergoing fine needle aspiration cytology (FNAC) with rapid on-site evaluation between January 2017 and December 2021...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37855419/radiofrequency-ablation-for-thyroid-bethesda-iii-nodules-preliminary-results
#38
JOURNAL ARTICLE
Pi-Ling Chiang, Sheng-Dean Luo, Yen-Hsiang Chang, Chen-Kai Chou, Shun-Yu Chi, Yi-Fan Chen, Wei-Che Lin
PURPOSE: The purpose of this study was to evaluate the feasibility of radiofrequency ablation (RFA) for thyroid nodules with cytological atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS, Bethesda III). MATERIALS AND METHODS: A total of 28 adults presenting with 30 initial Bethesda III nodules underwent thyroid RFA at a single medical center. Thyroid nodules with Bethesda IV or V according to the second aspiration were excluded...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37855417/usefulness-of-second-131i-treatment-in-biochemical-persistent-differentiated-thyroid-cancer-patients
#39
JOURNAL ARTICLE
Carla Gambale, Alessandro Prete, Lea Contartese, Liborio Torregrossa, Francesca Bianchi, Eleonora Molinaro, Gabriele Materazzi, Rossella Elisei, Antonio Matrone
BACKGROUND: Second 131I treatment is commonly performed in clinical practice in patients with differentiated thyroid cancer and biochemical incomplete or indeterminate response (BiR/InR) after initial treatment. OBJECTIVE: The objective of the is study is to evaluate the clinical impact of the second 131I treatment in BiR/InR patients and analyze the predictive factors for structural incomplete response (SiR). PATIENTS AND METHODS: One hundred fifty-three BiR/InR patients after initial treatment who received a second 131I treatment were included in the study...
December 1, 2023: European Thyroid Journal
https://read.qxmd.com/read/37855416/activation-of-mitogen-activated-protein-kinase-signaling-and-development-of-papillary-thyroid-carcinoma-in-thyroid-stimulating-hormone-receptor-d633h-knockin-mice
#40
JOURNAL ARTICLE
Markus Eszlinger, Alexandra Stephenson, Shideh Mirhadi, Konrad Patyra, Michael F Moran, Moosa Khalil, Jukka Kero, Ralf Paschke
OBJECTIVE: Nonautoimmune hyperthyroidism (NAH) is rare and occurs due to a constitutively activating thyroid stimulating hormone receptor (TSHR) mutation. In contrast to other thyroid nodules, no further evaluation for malignancy is recommended for hot thyroid nodules. In the first model for NAH in mice nearly all homozygous mice had developed papillary thyroid cancer by 12 months of age. METHODS: To further evaluate these mice, whole exome sequencing and phosphoproteome analysis were employed in a further generation of mice to identify any other mutations potentially responsible and to identify the pathways involved in thyroid carcinoma development...
December 1, 2023: European Thyroid Journal
journal
journal
47637
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.